Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...
Mankind Pharma, Ajanta Pharma, Sun Pharma, Zydus Life are the top picks within the Pharma space highlighted by Jefferies, who ...
Fitness guru Jillian Michaels exposes how major corporations profit from America's sickness in new Fox Nation special, "Toxic ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry.Deep ...
It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
India's Torrent Pharmaceuticals is set to raise up to 125 billion rupees ($1.4 billion) through short-duration bond sales in January, in one of the latest acquisition-funding deals, two bankers said.
NDT Pharmaceuticals’ Wholly Owned Subsidiary Good Salt Life, Inc. Advances Toward Key Regulatory Milestones for Clean ...
US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...
Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...
Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock sinks as market gains: What you should know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback